Artios, Novartis form cancer therapies collaboration
The deal could be worth as much as $1.3 billion to Artios
7th April 2021
Latest news
Fund opens to boost UK life sciences manufacturing
The £20 million fund will boost the UK's life sciences manufacturing capabilities, creating new economic opportunities and highly skilled jobs
7th April 2021
UK rolls out Moderna's COVID vaccine
The vaccine is the third to be approved for use in the UK to protect against COVID-19
7th April 2021
PharmaTimes announces the launch of the Communications Awards for 2021
The 2021 Communications Awards have opened their doors for entry, inviting the very best in pharma communications to come forward and claim first prize.
6th April 2021
NICE backs restricted use of Ondexxya
Funding backed for reversal of gastrointestinal bleeds but not for intracranial haemorrhage
6th April 2021
EC approval for Ontozry
The drug offers new hope for epilepsy patients with focal-onset seizures
6th April 2021
Researchers link to facilitate cheaper biologics
The parties intend to develop more cost-effective ways of producing biologic medicines
6th April 2021
Thousands to benefit from five-minute breast cancer treatment
NHS England is rolling out Roche's new combined treatment Phesgo, which drastically cuts administration time
6th April 2021
Twice-weekly coronavirus tests for all
Everyone in England, including those without symptoms, will be able to take a free rapid coronavirus test twice a week
6th April 2021
PharmaTimes are proud to announce the launch of Marketer of the Year 2021
Celebrating and uncovering exceptional pharma marketing talent for nearly three decades, the Marketer of the Year competition has launched for 2021.
1st April 2021
FDA green light for Sarclisa combo in multiple myeloma
CD38 inhibitor approved in combination with carfilzomib and dexamethasone
1st April 2021
Cancer research in the UK faces ‘perfect storm’ of funding cuts
Experts have raised ‘serious concerns’ over government plans for UK science funding
1st April 2021
Opdivo plus Cabometyx approved in the EU for advanced renal cancer
Opdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer's Sutent in a Phase III trial
1st April 2021
Positive results for Pfizer/BioNTech’s COVID-19 vaccine in 12-15 year olds
The vaccine demonstrated 100% efficacy in a Phase III trial in adolescents aged 12 to 15 years old
1st April 2021
Just 2 weeks left until INTCR 2021 closes for entry
The 2021 International Clinical Researcher of the Year competition will be closing for entry on the 16th of April.
31st March 2021
